US/UK/Canada

Share

Contacts

  • General Press Enquiries
    For general press enquiries please contact the AbbVie Corporate Communications team at UKMediaRelations@abbvie.com or call us on 01628 925200
    01628 925200
    https://twitter.com/abbvieuk
    • Pick a time period -
    Tags ( Active)

    NICE Recommends TEPKINLY[®] ▼ (epcoritamab), a Subcutaneous Bispecific Antibody for Adults With Relapsed/Refractory (R/R) Follicular Lymphoma (FL) After Two or More Lines of Systemic Therapy

    · Epcoritamab can now be accessed as a treatment option for adults with follicular lymphoma who have received two or more systemic treatments, only if epcoritamab is stopped after 3 years of treatment or earlier if the lymphoma progresses.[1] · The NICE recommendation is based on the single-arm Phase 1/2 EPCORE NHL-1 trial, where epcoritamab demonstrated responses in people whose cancer has returned or has not responded to at least two treatments.[2] · Follicular lymphoma is an incurable blood cancer that affects around 2,300 people in the UK every year, it is a challenging form

    AbbVie’s First in Class Therapy ELAHERE[®] ▼ (mirvetuximab soravtansine) Licensed by the MHRA for the Treatment of Eligible Adult Patients with Platinum-Resistant Ovarian Cancer

    For UK consumer, trade and medical media only. · Mirvetuximab soravtansine is the first folate receptor-alpha (FRα) targeted antibody-drug conjugate (ADC) licensed in the UK for the treatment of adults with platinum-resistant high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens, and who test positive for high levels of FRα.[1] · Mirvetuximab soravtansine demonstrated progression free survival and overall survival benefit in a Phase 3 trial in platinum-resistant ovarian cancer compared with

    Allergan Aesthetics’ BOTOX[®] (botulinum toxin type A) receives MHRA approval for the temporary improvement in the appearance of moderate to severe platysma prominence (platysma bands )[1]

    PRESS RELEASE – For UK Medical and Trade Media Only · The first and only UK approved non-surgical aesthetic neurotoxin treatment to temporarily improve the appearance of moderate to severe platysma prominence in adults seen at maximum contraction, when the severity has an important psychological impact in adult patients.[1] · Since contraction of the platysma muscle is involved in expressing negative emotions, platysma prominence can misrepresent a patient's emotional state. This negatively impacts self-esteem and quality of life, besides causing an appearance of ageing.[2]MARLOW,

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe